Daraxonrasib Demonstrates Unprecedented Overall Survival Benefit in Pivotal Phase 3 RASolute 302 Clinical Trial in Patients with Metastatic Pancreatic Cancer
Go back to Daraxonrasib Demonstrates Unprecedented Overall Survival Benefit in Pivotal Phase 3 RASolute 302 Clinical Trial in Patients with Metastatic Pancreatic Cancer| (NASDAQ: RVMD) | Delayed: 162.99 +5.22 (3.31%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $157.77 | 52 Week High | $ | |||
| Open | $160.65 | 52 Week Low | $ | |||
| Day High | $164.78 | P/E | N/A | |||
| Day Low | $158.40 | EPS | $ | |||
| Volume | 4,702,507 | |||||
